<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
Moderna Inc (NASDAQ: MRNA) announced data from the AstraZeneca Plc (NASDAQ: AZN)-led Phase 2 (EPICCURE) study evaluating AZD8601 in patients undergoing coronary artery bypass grafting (CABG). AZD8601 is an mRNA therapeutic that encodes for vascular endothelial growth factor-A (VEGF-A).
...read full article on Benzinga
